Donor Diabetes Mellitus Is an Independent Risk Factor for Graft Loss in HCV Positive but Not HCV Negative Liver Transplant Recipients

Division of Gastroenterology, Massachusetts General Hospital, 55 Fruit St, Blake 4, Boston, MA, 02114, USA, .
Digestive Diseases and Sciences (Impact Factor: 2.61). 08/2012; 58(2). DOI: 10.1007/s10620-012-2345-7
Source: PubMed


Background and aims:
Graft survival in HCV (hepatitis C virus) infected recipients is worse than those transplanted for other liver diseases. We studied whether several donor cardiovascular risk factors (including advanced age, smoking, hypertension, and diabetes mellitus) contribute to worse outcomes for HCV positive and HCV negative liver transplant recipients.

We obtained data from the United Network for Organ Sharing on all adult liver transplants performed in the United States between January 1, 1998 and December 31, 2003. In total, 27,033 transplant cases were evaluated. Independent predictors of graft survival were determined using Cox proportional hazards regression analysis after controlling for factors previously found to be associated with differences in transplant outcomes.

Donor diabetes was a strong independent risk factor for graft failure [hazard ratio (HR) = 1.20, p = 0.006] only in HCV positive recipients. Neither donor smoking status nor hypertension predicted graft loss in either cohort. Consistent with previous studies, advanced donor age, donation after cardiac death, height, and African American donor all predicted graft loss amongst both cohorts.

Accounting for donor diabetes in relation to recipient HCV status in the selection of liver recipients may result in improved graft survival.

Full-text preview

Available from:
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: Hepatitis C virus (HCV)-related liver disease, including cirrhosis and hepatocellular carcinoma is the main indication for liver transplantation (LT) worldwide. Post-transplant HCV re-infection is almost universal and results in accelerated progression from acute hepatitis to chronic hepatitis, and liver cirrhosis. Comprehension and treatment of recurrent HCV infection after LT have been major issues for all transplant hepatologists and transplant surgeons for the last decades. The aim of this paper is to review the evolution of our knowledge on the natural history of HCV recurrence after LT, including risk factors for disease progression, and antiviral therapy. We will focus our attention on possible ways (present and future) to improve the final long-term results of LT for HCV-related liver disease.
    World Journal of Gastroenterology 08/2014; 20(32):11069-11079. DOI:10.3748/wjg.v20.i32.11069 · 2.37 Impact Factor
  • [Show abstract] [Hide abstract]
    ABSTRACT: Background Hepatitis C virus (HCV) is associated with metabolic manifestations including insulin resistance and diabetes through various mechanisms. Whether HCV infection is associated with an increased risk of post-transplant diabetes in liver transplant recipients is unclear.AimTo assess the association of HCV infection with post-transplant diabetes.Methods All liver transplant recipients infected with hepatitis C (exposed) and hepatitis B (HBV) (controls) with post-transplant follow-up from the Scientific Registry of Transplant Recipients (2003–2012) were included.ResultsA total of 17 121 HCV patients and 1450 HBV controls were included in this observational study. Subjects with HCV were more likely to be overweight and obese at transplant, but the rate of pre-transplant diabetes of 13.7% was similar to HBV (P > 0.05). Post-transplant, 32.5% of HCV patients and 27.5% of HBV patients had diabetes (P < 0.0001). This difference was observed starting as early as 6 months post-transplant: 22.5% HCV and 18.9% HBV (P = 0.0043). With longer follow-up, both the cumulative and incidental risks of developing post-transplant diabetes were consistently higher in HCV patients. In particular, by 5 years post-transplant, both the relative risk of having diabetes [1.18 (1.08–1.29), P = 0.0002] and the hazard ratio for time to developing diabetes [1.27 (1.15–1.41), P < 0.0001] were significantly higher in HCV patients compared to HBV patients. In multivariate analysis, after adjustment for confounders including the use of immunosuppressants, hepatitis C infection was independently associated with developing post-transplant diabetes: aHR = 1.55 (1.34–1.79), P < 0.0001.Conclusion Hepatitis C infection is associated with a higher risk of post-transplant diabetes that persists up to 5 years post-transplant.
    Alimentary Pharmacology & Therapeutics 11/2014; 41(2). DOI:10.1111/apt.13027 · 5.73 Impact Factor
  • [Show abstract] [Hide abstract]
    ABSTRACT: Donor age has become the dominant donor factor used to predict graft failure (GF) after liver transplantation (LT) in HCV recipients. To develop and validate a model of Corrected Donor Age (CDA) for HCV LT recipients that transforms the risk of other donor factors into the scale of donor age. We analyzed all first LT recipients with HCV in the UNOS registry from 1/1998-12/2007 (development cohort, n=14,538) and 1/2008-12/2011 (validation cohort, n=7,502) using Cox regression, excluding early GF (<90 days from LT). Accuracy in predicting 1yr GF (death or Re-LT) was assessed with the net reclassification index (NRI). In the development cohort, controlling for pre-LT recipient factors and geo-temporal trends (UNOS region, LT year), the following donor factors were independent predictors of GF (Hazard Ratio); all p<0.05; donor age (1.02/yr), circulatory death (DCD) (1.31), diabetes (1.23), height<160cm (1.13), AST>120 U/L (1.10), female (0.94), cold ischemia time (CIT) (1.02/hr), donor non-AA: recipient AA (1.65). Transforming these risk factors into the donor age scale yielded the following: DCD=+16yrs, diabetes=+12yrs, height<160cm=+7yrs, AST >120 U/L=+5yrs, female=-4yrs, CIT=+1yr/hr>8hrs and -1yr/hr<8 hrs. There was a large effect of donor-recipient race combinations; +29yrs for donor non-AA: recipient AA but only +5yrs for donor AA: recipient AA, and -2yrs for donor AA: recipient non-AA. In a validation cohort, CDA better classified risk of 1yr GF versus actual age (NRI 4.9%, p=0.009) and versus the donor risk index (9.0%, p<0.001). The CDA, compared to actual donor age, provides an intuitive and superior estimation of graft quality for HCV-positive LT recipients since it incorporates additional factors that impact LT GF rates. This article is protected by copyright. All rights reserved. © 2015 American Association for the Study of Liver Diseases.
    Liver Transplantation 06/2015; 21(8). DOI:10.1002/lt.24194 · 4.24 Impact Factor